Selected research
Market Structure
Global Psychoactive Substances Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Psychoactive Substances market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Psychoactive Substances is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Psychoactive Substances include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Psychoactive Substances market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Psychoactive Substances and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Psychoactive Substances revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Psychoactive Substances market size, projected growth trends, production technologies, key applications, and end-use industries.
Psychoactive Substances Segment by Company
Alpha-CAT
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Cape Bouvard Technologies Pty Ltd
Cyrelian Pty Ltd.
Enecta.
GD Pharma
GW Pharmaceuticals PLC.
MedReleaf Australia
Teewinot Life Sciences
Tilray
Zynerba Pharmaceuticals
Psychoactive Substances Segment by Type
Cannabinoids
Hallucinogens
Stimulants
Depressants
Psychoactive Substances Segment by Application
Neuropathic Disorders
Spasticity
Cancer
Psychoactive Substances Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Psychoactive Substances in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psychoactive Substances industry.
Chapter 3: Detailed analysis of Psychoactive Substances companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychoactive Substancesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cannabinoids
- Hallucinogens
- Stimulants
- Depressants
Applications
- Neuropathic Disorders
- Spasticity
- Cancer
Companies covered
- Alpha-CAT
- AusCann Group Holdings Pty Ltd.
- Cannabics Pharmaceuticals Inc.
- Cape Bouvard Technologies Pty Ltd
- Cyrelian Pty Ltd.
- Enecta.
- GD Pharma
- GW Pharmaceuticals PLC.
- MedReleaf Australia
- Teewinot Life Sciences
- Tilray
- Zynerba Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Psychoactive Substances Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Cannabinoids
- 1.2.3 Hallucinogens
- 1.2.4 Stimulants
- 1.2.5 Depressants
- 1.3 Market Analysis by Application
- 1.3.1 Global Psychoactive Substances Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Neuropathic Disorders
- 1.3.3 Spasticity
- 1.3.4 Cancer
- 1.4 Global Market Growth Prospects
- 1.5 Global Psychoactive Substances Growth Trends by Region
- 1.5.1 Global Psychoactive Substances Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Psychoactive Substances Market Size by Region (2021-2026)
- 1.5.3 Psychoactive Substances Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Psychoactive Substances Market Dynamics
- 2.1 Psychoactive Substances Industry Trends
- 2.2 Psychoactive Substances Industry Drivers
- 2.3 Psychoactive Substances Industry Opportunities and Challenges
- 2.4 Psychoactive Substances Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Psychoactive Substances Revenue by Company (2021-2026)
- 3.2 Global Psychoactive Substances Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Psychoactive Substances Key Company Head office and Area Served
- 3.4 Global Psychoactive Substances Company, Product Type & Application
- 3.5 Global Psychoactive Substances Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Psychoactive Substances Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Psychoactive Substances Players Market Share by Revenue in 2025
- 3.6.3 2025 Psychoactive Substances Tier 1, Tier 2, and Tier 3
4 Psychoactive Substances Market by Type
- 4.1 Global Psychoactive Substances Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Psychoactive Substances Market Size by Type (2021-2032)
- 4.3 Global Psychoactive Substances Market Size Share by Type (2021-2032)
5 Psychoactive Substances Market by Application
- 5.1 Global Psychoactive Substances Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Psychoactive Substances Market Size by Application (2021-2032)
- 5.3 Global Psychoactive Substances Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Alpha-CAT
- 6.1.1 Alpha-CAT Company Information
- 6.1.2 Alpha-CAT Business Overview
- 6.1.3 Alpha-CAT Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Alpha-CAT Psychoactive Substances Product Portfolio
- 6.1.5 Alpha-CAT Recent Developments
- 6.2 AusCann Group Holdings Pty Ltd.
- 6.2.1 AusCann Group Holdings Pty Ltd. Company Information
- 6.2.2 AusCann Group Holdings Pty Ltd. Business Overview
- 6.2.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
- 6.2.5 AusCann Group Holdings Pty Ltd. Recent Developments
- 6.3 Cannabics Pharmaceuticals Inc.
- 6.3.1 Cannabics Pharmaceuticals Inc. Company Information
- 6.3.2 Cannabics Pharmaceuticals Inc. Business Overview
- 6.3.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
- 6.3.5 Cannabics Pharmaceuticals Inc. Recent Developments
- 6.4 Cape Bouvard Technologies Pty Ltd
- 6.4.1 Cape Bouvard Technologies Pty Ltd Company Information
- 6.4.2 Cape Bouvard Technologies Pty Ltd Business Overview
- 6.4.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
- 6.4.5 Cape Bouvard Technologies Pty Ltd Recent Developments
- 6.5 Cyrelian Pty Ltd.
- 6.5.1 Cyrelian Pty Ltd. Company Information
- 6.5.2 Cyrelian Pty Ltd. Business Overview
- 6.5.3 Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
- 6.5.5 Cyrelian Pty Ltd. Recent Developments
- 6.6 Enecta.
- 6.6.1 Enecta. Company Information
- 6.6.2 Enecta. Business Overview
- 6.6.3 Enecta. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Enecta. Psychoactive Substances Product Portfolio
- 6.6.5 Enecta. Recent Developments
- 6.7 GD Pharma
- 6.7.1 GD Pharma Company Information
- 6.7.2 GD Pharma Business Overview
- 6.7.3 GD Pharma Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 GD Pharma Psychoactive Substances Product Portfolio
- 6.7.5 GD Pharma Recent Developments
- 6.8 GW Pharmaceuticals PLC.
- 6.8.1 GW Pharmaceuticals PLC. Company Information
- 6.8.2 GW Pharmaceuticals PLC. Business Overview
- 6.8.3 GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
- 6.8.5 GW Pharmaceuticals PLC. Recent Developments
- 6.9 MedReleaf Australia
- 6.9.1 MedReleaf Australia Company Information
- 6.9.2 MedReleaf Australia Business Overview
- 6.9.3 MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 MedReleaf Australia Psychoactive Substances Product Portfolio
- 6.9.5 MedReleaf Australia Recent Developments
- 6.10 Teewinot Life Sciences
- 6.10.1 Teewinot Life Sciences Company Information
- 6.10.2 Teewinot Life Sciences Business Overview
- 6.10.3 Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Teewinot Life Sciences Psychoactive Substances Product Portfolio
- 6.10.5 Teewinot Life Sciences Recent Developments
- 6.11 Tilray
- 6.11.1 Tilray Company Information
- 6.11.2 Tilray Business Overview
- 6.11.3 Tilray Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Tilray Psychoactive Substances Product Portfolio
- 6.11.5 Tilray Recent Developments
- 6.12 Zynerba Pharmaceuticals
- 6.12.1 Zynerba Pharmaceuticals Company Information
- 6.12.2 Zynerba Pharmaceuticals Business Overview
- 6.12.3 Zynerba Pharmaceuticals Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
- 6.12.5 Zynerba Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Psychoactive Substances Market Size (2021-2032)
- 7.2 North America Psychoactive Substances Market Size by Type
- 7.2.1 North America Psychoactive Substances Market Size by Type (2021-2026)
- 7.2.2 North America Psychoactive Substances Market Size by Type (2027-2032)
- 7.2.3 North America Psychoactive Substances Market Share by Type (2021-2032)
- 7.3 North America Psychoactive Substances Market Size by Application
- 7.3.1 North America Psychoactive Substances Market Size by Application (2021-2026)
- 7.3.2 North America Psychoactive Substances Market Size by Application (2027-2032)
- 7.3.3 North America Psychoactive Substances Market Share by Application (2021-2032)
- 7.4 North America Psychoactive Substances Market Size by Country
- 7.4.1 North America Psychoactive Substances Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Psychoactive Substances Market Size by Country (2021-2026)
- 7.4.3 North America Psychoactive Substances Market Size by Country (2027-2032)
- 7.4.4 North America Psychoactive Substances Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Psychoactive Substances Market Size (2021-2032)
- 8.2 Europe Psychoactive Substances Market Size by Type
- 8.2.1 Europe Psychoactive Substances Market Size by Type (2021-2026)
- 8.2.2 Europe Psychoactive Substances Market Size by Type (2027-2032)
- 8.2.3 Europe Psychoactive Substances Market Share by Type (2021-2032)
- 8.3 Europe Psychoactive Substances Market Size by Application
- 8.3.1 Europe Psychoactive Substances Market Size by Application (2021-2026)
- 8.3.2 Europe Psychoactive Substances Market Size by Application (2027-2032)
- 8.3.3 Europe Psychoactive Substances Market Share by Application (2021-2032)
- 8.4 Europe Psychoactive Substances Market Size by Country
- 8.4.1 Europe Psychoactive Substances Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Psychoactive Substances Market Size by Country (2021-2026)
- 8.4.3 Europe Psychoactive Substances Market Size by Country (2027-2032)
- 8.4.4 Europe Psychoactive Substances Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Psychoactive Substances Market Size (2021-2032)
- 9.2 China Psychoactive Substances Market Size by Type
- 9.2.1 China Psychoactive Substances Market Size by Type (2021-2026)
- 9.2.2 China Psychoactive Substances Market Size by Type (2027-2032)
- 9.2.3 China Psychoactive Substances Market Share by Type (2021-2032)
- 9.3 China Psychoactive Substances Market Size by Application
- 9.3.1 China Psychoactive Substances Market Size by Application (2021-2026)
- 9.3.2 China Psychoactive Substances Market Size by Application (2027-2032)
- 9.3.3 China Psychoactive Substances Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Psychoactive Substances Market Size (2021-2032)
- 10.2 Asia Psychoactive Substances Market Size by Type
- 10.2.1 Asia Psychoactive Substances Market Size by Type (2021-2026)
- 10.2.2 Asia Psychoactive Substances Market Size by Type (2027-2032)
- 10.2.3 Asia Psychoactive Substances Market Share by Type (2021-2032)
- 10.3 Asia Psychoactive Substances Market Size by Application
- 10.3.1 Asia Psychoactive Substances Market Size by Application (2021-2026)
- 10.3.2 Asia Psychoactive Substances Market Size by Application (2027-2032)
- 10.3.3 Asia Psychoactive Substances Market Share by Application (2021-2032)
- 10.4 Asia Psychoactive Substances Market Size by Country
- 10.4.1 Asia Psychoactive Substances Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Psychoactive Substances Market Size by Country (2021-2026)
- 10.4.3 Asia Psychoactive Substances Market Size by Country (2027-2032)
- 10.4.4 Asia Psychoactive Substances Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Psychoactive Substances Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Psychoactive Substances Market Size by Type
- 11.2.1 South America, Middle East & Africa Psychoactive Substances Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Psychoactive Substances Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Psychoactive Substances Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Psychoactive Substances Market Size by Application
- 11.3.1 South America, Middle East & Africa Psychoactive Substances Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Psychoactive Substances Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Psychoactive Substances Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Psychoactive Substances Market Size by Country
- 11.4.1 South America, Middle East & Africa Psychoactive Substances Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Psychoactive Substances Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Psychoactive Substances Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Psychoactive Substances Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst